Our results can then be viewed as supportive, but not conclusive, evidence of higher costs for drugs with lower therapeutic significance ratings for the period studied. REFERENCES DiMasi, J.A., Hansen, R.W., Grabowski, H.G., Lasagna, L., 1991. Cost of innovation in the pharmaceutical industry. 10(2), 107-142. Journal of Health Economics DiMasi, J.A., Hansen, R.W., Grabowski, H.G., 2003. The price of innovation: new estimates of drug development costs. 22(2), 151-185. Journal of Health Economics DiMasi, J.A., Grabowski, H.G., 2007. The cost of biopharmaceutical R&D: Is biotech different? 28(4-5), 285-291. Managerial & Decision Economics DiMasi, J.A., Feldman, L., Seckler, A., Wilson, A., 2010. Trends in risks associated with new drug development: Success rates for investigational drugs. Clinical Pharmacology & 87(3), 272-277. Therapeutics DiMasi, J.A., Reichert, J.M., Feldman, L., Malins, A., 2013. Clinical approval success rates for investigational cancer drugs. 94(3), 329-335. Clinical Pharmacology & Therapeutics Guedj, I., Sharfstein, D. 2004. Organization Scope and Investment: Evidence from the Drug NBER Working Paper Development Strategies and Performance of Biopharmaceutical Firms. 10933. (url: [Accessed July 23, 2014]).
Our results can then be viewed as supportive, but not conclusive, evidence of higher costs for drugs with lower therapeutic significance ratings for the period studied. REFERENCES DiMasi, J.A., Hansen, R.W., Grabowski, H.G., Lasagna, L., 1991. Cost of innovation in the pharmaceutical industry. Journal of Health Economics 10(2), 107-142. DiMasi, J.A., Hansen, R.W., Grabowski, H.G., 2003. The price of innovation: new estimates of drug development costs. Journal of Health Economics 22(2), 151-185. DiMasi, J.A., Grabowski, H.G., 2007. The cost of biopharmaceutical R&D: Is biotech different? Managerial & Decision Economics 28(4-5), 285-291. DiMasi, J.A., Feldman, L., Seckler, A., Wilson, A., 2010. Trends in risks associated with new drug development: Success rates for investigational drugs. Clinical Pharmacology & Therapeutics 87(3), 272-277. DiMasi, J.A., Reichert, J.M., Feldman, L., Malins, A., 2013. Clinical approval success rates for investigational cancer drugs. Clinical Pharmacology & Therapeutics 94(3), 329-335. Guedj, I., Sharfstein, D. 2004. Organization Scope and Investment: Evidence from the Drug Development Strategies and Performance of Biopharmaceutical Firms. NBER Working Paper 10933. (url: [Accessed July 23, 2014]).
1-s2.0-S0167629616000291-mmc1.docx